TPCW
BBNX

TD Private Client Wealth’s Beta Bionics BBNX Stock Holding History

TD Private Client Wealth’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-66
Closed -$2.01K – 1753
2025
Q4 		$2.01K Hold
66
– – ﹤0.01% 1272
2025
Q3 		$1.31K Hold
66
– – ﹤0.01% 1296
2025
Q2 		$961 Buy
+66
New +$934 ﹤0.01% 1295

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TD Private Client Wealth's BBNX Position: Q1 2026 in Review

TD Private Client Wealth sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 66 shares — an estimated $2.01K sold.

TD Private Client Wealth first reported a position in BBNX in Q2 2025 and held it in 3 quarters. The position peaked at $2.01K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • TD Private Client Wealth reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
  • TD Private Client Wealth sold 66 Beta Bionics shares in Q1 2026, an estimated $2.01K.
  • TD Private Client Wealth first reported a position in Beta Bionics in Q2 2025 and held it in 3 quarters.
  • TD Private Client Wealth's Beta Bionics position peaked at $2.01K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.